An Unusual Case of Colon Perforation With Multiple Transmural Ulcers After Use of Polmacoxib and Everolimus in a Metastatic Breast Cancer Patient
- Author:
In-Gyu SONG
1
;
Kyung Uk JUNG
;
Hyung Ook KIM
;
Hungdai KIM
;
Ho-Kyung CHUN
Author Information
- Publication Type:Case Report
- From:Annals of Coloproctology 2021;37(2):120-124
- CountryRepublic of Korea
- Language:English
- Abstract: Everolimus (Afinitor) is an inhibitor of mammalian target of rapamycin. Polmacoxib (Acelex) is a nonsteroidal anti-inflammatory drug that belongs to the cyclooxygenase-2 (COX-2) inhibitor family and is mainly used for treatment of arthritis. Intestinal perforation has not been reported previously as a complication of everolimus, and perforation of the lower intestinal tract caused by a selective COX-2 inhibitor is extremely rare. We present here a case of colon perforation that occurred after use of polmacoxib in a metastatic breast cancer patient who had been treated with everolimus for the preceding six months.
